Clinical Trials Sponsored by Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company

Total 45 results

Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo...

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

Atrial Fibrillation

Hong Kong
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

Completed

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Acute Coronary Syndrome (ACS)

Taiwan
Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Completed

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Atrial Fibrillation

United Kingdom
Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo...

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

Atrial Fibrillation

Thailand
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Daiichi Sankyo, Inc.

Completed

Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR)

Atrial Fibrillation

Turkey
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo...

Completed

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Essential Hypertension

Korea, Republic of
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Hypercholesterolemia | Mixed Dyslipidemia

Austria, United Kingdom, Italy, Germany, Belgium
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (ETNA-VTE)

Venous Thromboembolism

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI)

Atrial Fibrillation

Italy, Netherlands, Spain, Korea, Republic of, Portugal, Hungary, Serbia, United Kingdom, Germany, Belgium, Taiwan, Austria, Switzerland, France, Ukraine, Lithuania, Poland, Romania
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (ELIMINATE-AF)

Atrial Fibrillation

Spain, Belgium, Korea, Republic of, United Kingdom, Germany, Italy, Taiwan, Hungary, Czechia, Canada, Poland
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

The Confirmatory Olmesartan Plaque Regression Study (CONFIRM)

Essential Hypertension | Carotid Plaque

Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Hypertension

Spain
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
UNICANCER
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Active, not recruiting

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis (DAISY)

Breast Tumors

France
AstraZeneca
Daiichi Sankyo Co., Ltd.; Daiichi Sankyo Company, Limited

Active, not recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)

Metastatic Breast Cancer

Belgium, United States, Taiwan, Korea, Republic of, Brazil, Russian Federation, Canada, Australia, France, Mexico
Menarini Group
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Hypertension

Poland, Germany, Israel, Romania, Italy, Denmark, Czechia, Croatia
Heidelberg University
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Unknown

Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Patients With Acute Coronary Syndrome

Germany
University Hospital Heidelberg
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)

Acute Myeloid Leukemia
University Hospital Inselspital, Berne
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19 (CONVINCE)

COVID-19 | SARS-CoV Infection

Belgium, Switzerland, Italy
Keimyung University Dongsan Medical Center
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company

Recruiting

Resolution of Thrombi in Left Atrial Appendage With Edoxaban (REFLEX)

Atrial Fibrillation | Left Atrial Appendage Thrombosis

Korea, Republic of
PETHEMA Foundation
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Syntax for Science, S.L

Active, not recruiting

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Acute Myeloid Leukemia

Spain
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction (ACCOAST)

Acute Coronary Syndromes

Israel, Italy, Germany, Belgium, Poland, France, Austria, Netherlands, Turkey, Hungary, Lithuania, Romania, Canada, Slovakia, Czech Republic, Finland, Latvia, Portugal, Sweden
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease (GENERATIONS)

Coronary Artery Disease

Netherlands, Sweden, United States, Ireland
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease (FEATHER)

Coronary Artery Disease

Sweden, Netherlands, United States, Ireland
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Terminated

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) (TRIGGER-PCI)

Coronary Artery Disease (CAD)

United States, Germany
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Acute Coronary Syndrome

China, Thailand, Taiwan, Korea, Republic of
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Terminated

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Acute Coronary Syndromes

Germany
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

Anemia, Sickle Cell

United Kingdom
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC; Janssen-Cilag G.m.b.H; Daiichi Sankyo Europe, GmbH,...

Recruiting

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT (CONNECT)

Advanced Solid Tumor

Germany
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für...

Terminated

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH)

Atrial High Rate Episodes

Austria, Belgium, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Ukraine, United Kingdom, Denmark
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Preventicus GmbH; Corsano... and other collaborators

Completed

The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9) (Smart in OAC)

Atrial Arrhythmia

Germany, Poland, Spain
Eli Lilly and Company
Duke Clinical Research Institute; Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS)

Acute Coronary Syndrome

Argentina, Brazil, Canada, Italy, China, Puerto Rico, Australia, Romania, Russian Federation, France, Germany, United States, Belgium, Bulgaria, Poland, Ukraine, United Kingdom, Colombia, Hungary, Philippines, Croatia, Denmark, India, Chil... and more
Johannes Gutenberg University Mainz
Sanofi; Bayer; Boehringer Ingelheim; German Federal Ministry of Education and Research and other collaborators

Completed

Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme (thrombEVAL)

Atrial Fibrillation | Venous Thromboembolism | Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use

Germany

Clinical Trials Sponsored by Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations